TheraRadar
← Back
Data updated: Jul 17, 2026

SHREE HARI INTL

Generics

SHREE HARI INTL is a generic drug manufacturer focused on Immunology.

1985
Since
3
Drugs
-
Trials
0
New Drugs (2yr)

SHREE HARI INTL's Key Drugs

SHREE HARI INTL's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

SHREE HARI INTL's Recent FDA Approvals

New NDA/BLA approvals for SHREE HARI INTL over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

SHREE HARI INTL's Therapeutic Areas

SHREE HARI INTL's approved drugs and pipeline span 1 therapeutic area, led by Immunology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Immunology 100%
1 drugs

SHREE HARI INTL's Top Competitors

SHREE HARI INTL's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and AbbVie. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

SHREE HARI INTL Pipeline Snapshot

Active clinical trials for SHREE HARI INTL across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Immunology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling